OOIR: Observatory of International Research

Papers

(The TQCC of Annals of Hepatology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
P- 16 HEPATOCELLULAR CARCINOMA IN CENTRAL AMERICA: A MULTIDISCIPLINARY APPROACH IN A COSTA RICAN COHORT	500
O-1 SEROPREVALENCE AND MOTHER-TO-CHILD TRANSMISSION OF HEPATITIS B AND C VIRUSES AMONG PREGNANT WOMEN IN A MATERNAL AND CHILDREN HOSPITAL FROM THE PROVINCE OF BUENOS AIRES	143
P- 43 HCV TESTING AND TREATMENT IN FOUR BRAZILIANS’ CORRECTIONAL SETTINGS	64
P-8 TRENDS IN ALCOHOL-ASSOCIATED CIRRHOSIS IN CHILE: A POPULATION STUDY BETWEEN 2001 TO 2020.	62
O2- CHARACTERIZATION OF STEATOTIC LIVER DISEASE AND THE ROLE OF GENETIC BACKGROUND IN LATIN AMERICA	53
P-46 IMMUNOSUPPRESSION IN POST LIVER TRANSPLANTATION: REVIEW OF THE EXPERIENCE IN A CHILEAN UNIVERSITY HOSPITAL	48
Development of a biodegradable prosthesis through tissue engineering, for the organ-replacement or substitution of the extrahepatic bile duct	44
P-110 CHANGES IN THE CLINICAL PRESENTATION OF PRIMARY BILIARY CHOLANGITIS (PBC) OVER THE YEARS IN A UNIVERSITY CENTER IN ARGENTINA	44
Tumor-associated macrophages contribute to cholangiocarcinoma progression and chemoresistance through activation of ID1	41
Elevated lactate/albumin ratio as a novel predictor of in-hospital mortality in hospitalized cirrhotics	39
Comment on “burden of disease and risk factors for primary liver cancer by etiology in the United States, 1990–2021: Results from the global burden of disease study, 2021”	39
CRITICAL MEDIATORS OF INFLAMMATION-DRIVEN HEPATOCARCINOGENESIS INDUCED BY METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE	38
THE RELATIONSHIP BETWEEN QUALITY OF LIFE IN ADULT SUBJECTS WITH COMPENSATED LIVER CIRRHOSIS AND BACTERIAL OVERGROWTH	37
IMPROVEMENT OF CARDIOVASCULAR RISK ASSESSMENT ON A COHORT OF PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)	36
PLANT-DERIVED MONOTERPENE SYNERGIZES WITH SORAFENIB TO SUPPRESS DRUG-TRIGGERED HEPATOCELLULAR CARCINOMA IN ANIMALS	35
AUTOIMMUNE HEPATITIS IN LATIN AMERICA: INSIGHTS FROM THE ALLATIN COHORT	34
INFLUENCE OF GLYCEMIC CONTROL ON THE SEVERITY OF HEPATIC STEATOLOGY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS	33
Neutrophil/lymphocyte index as a prognostic predictor in patients with primary biliary cholangitis	30
Skeletal muscle as a source of IGFBP-2 in a murine model of metabolic dysfunction associated with steatotic liver disease.	30
Acute Liver Failure due to Hepatitis A Virus: A Report of Two Cases	30
Characterization and determination of prevalence in autoimmune liver diseases in a tertiary center.	28
Etiology and find in portal vein thrombosis at the Hospital de Especialidades del Centro Médico Nacional La Raza	27
Levels of IGFBP-1, 3 and 7 in human serum induced by alcohol consumption, NAFLD and dual insult	27
Kasabach-Merritt syndrome in an adult treated by embolization prior to liver transplantation: a case report.	27
Examining genetic associations with hepatic steatosis in Mexican-origin adults	26

Short-term efficacy and safety of l-ornithine l-aspartate therapy in patients with cirrhosis and minimal hepatic encephalopathy: a real-life cohort study	26
Association of IFNL3 gene rs4803217 with spontaneous clearance of Hepatitis C virus in patients from West Mexico	25
P- 91 CHANGES IN EARLY VISUAL PERCEPTION IN PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY	25
Targeting cellular senescence as a therapeutic approach in non-alcoholic steatohepatitis	24
A thorny matter: Spur cell anemia	24
Activation of the NLRP3 inflammasome by CCl4 exacerbates hepatopathogenic diet-induced experimental NASH	23
Clinical and microbiological characteristics of bacterial infections in patients with cirrhosis. A prospective cohort study from Argentina and Uruguay	23
Genome-wide DNA methylation and transcriptomic analysis of liver tissues subjected to early ischemia/reperfusion injury upon human liver transplantation	22
Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms	22
A practical approach to the endoscopic management of biliary strictures after liver transplantation	21
Lipocalin-2 silencing alleviates sepsis-induced liver injury through inhibition of ferroptosis	20
Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990-2021 to 2045	20
P-19 ASSOCIATION OF TM6SF2 GENE POLYMORPHISMS WITH CARDIOVASCULAR RISK IN PATIENTS WITH METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN A HISPANIC ADULT POPULATION	20
Energy metabolism: An emerging therapeutic frontier in liver fibrosis	20
P-65 NEOPORTA WITH OR WITHOUT TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT AS A VIABLE TREATMENT OF CHRONIC PORTAL VEIN THROMBOSIS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS	20
DILI and Dress syndrome secondary to treatment with DoTbal, in a patient with tuberculosis at the rural hospital from Papantla – IMSS Bienestar	20
Correspondence: “A multisociety Delphi consensus statement on new fatty liver disease nomenclature”	20
Dietary macro and micronutrients associated with MASLD: Analysis of a national US cohort database	20
P-106 DIAGNOSTIC ACCURACY OF SHEAR-WAVE ELASTOGRAPHY IN METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE, A SINGLE CENTER REPORT	20
P-40 ASSOCIATION BETWEEN LIVER STIFFNESS MEASUREMENTS USING MR ELASTOGRAPHY AND PORTOSYSTEMIC SHUNTS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE	20
TSH and its Correlation in the Development of Fibrosis in Patients with Hypothyroidism in a Tertiary Care Hospital	19
Impact of neohepatic albumin-bilirubin scores on renal outcomes following living donor liver transplantation: a propensity score analysis	19
Epidemiology and natural history of chronic Hepatitis B in the Canadian province of Alberta from 2012 to 2021: A population-based study	19
Biological aging accelerates hepatic fibrosis: Insights from the NHANES 2017–2020 and genome-wide association study analysis	19
Data mining reveals novel gene drivers of lenvatinib resistance in hepatocellular carcinoma	19
Prevalence of fibrosis and steatosis determined by transient elastography and controlled attenuation parameter (Fibroscan®) in diabetic patients	17
Liver Injury Induced by Peumus boldus with Fatal Outcome. Case Report	17
Ceftriaxone versus cefotaxime in the treatment of spontaneous bacterial peritonitis	17
The Hepatic Effect of Sub-chronic Chronic Cadmium Exposure.	17
Mechanisms and therapeutic targets of mitochondria in the progression of metabolic dysfunction-associated steatotic liver disease	16
The dual role of HCV protein expression in communication between host cells presents potential applications in the treatment of liver fibrosis	16
Impact of hepatitis B surface antigen quantification on achieving a functional cure in patients with chronic hepatitis B: A systematic review and meta-analysis	16
Regression of fibrosis and portal hypertension in chronic liver disease: Endothelial perspectives and clinical implications	16
Moringa oleifera decreases biomarkers of oxidative stress in a murine NASH model	15
OP-3 HCV MICROELIMINATION PROGRAM IN HEMODIALYSIS PATIENTS: SUCCESS OF A MULTI-STAKEHOLDER PARTNERSHIP BASED ON A NATIONAL ERADICATION STRATEGY	15
Autoimmune hepatitis with superimposition of primary sclerosing cholangitis on non-specific chronic ulcerative colitis	15
An exploratory analysis of patient factors influencing acceptance of extended criteria liver grafts	15
Trajectories of patients relisted for liver transplantation	14
P-15 MMP-2 AND MMP-9 LEVELS IN ALCOHOLIC LIVER DISEASE, NON-ALCOHOLIC FATTY LIVER DISEASE AND CHRONIC HEPATITIS C	14
IGFBP2: a possible molecular link between liver, heart, and bloodstream during metabolic dysfunction-associated steatotic liver disease	14
OP-4 IMPLEMENTATION OF A RE-LINKAGE TO CARE STRATEGY IN PATIENTS WITH CHRONIC HEPATITIS C WHO WERE LOST TO FOLLOW-UP IN LATIN AMERICA	13
P-13 PREVALENCE, CHARACTERIZATION, AND SURVIVAL OF ACUTE ON CHRONIC LIVER FAILURE IN A LATIN AMERICAN COHORT: A MULTICENTER STUDY	13
Detection of Hepatitis C and risk factors in the general population of the Centro Médico Nacional La Raza	13
P-2 DE NOVO LIPOGENESIS MARKERS ARE INVOLVED IN METABOLIC ASSOCIATED FATTY LIVER DISEASE PROGRESSION IN BTBR OB/OB MICE	13
Treatment with nucleoside and nucleotide analogues in patients with chronic hepatitis B virus infection	13
P-123 HEPATOCELLULAR CARCINOMA SURVIVAL: EXPERIENCE OF THE MULTIDISCIPLINARY COMMITTEE AT HOSPITAL ESPECIALIDADES EUGENIO ESPEJO IN QUITO – ECUADOR	13
DRUG-INDUCED DUCTOPENIA IN THE SPANISH AND LATINDILI REGISTRIES	12
HEPATITIS C SCREENING AND GENDER DISPARITIES IN POSITIVITY RATES IN ARGENTINA	12
NURSING CARE STRATEGIES FOR INDIVIDUALS WITH VIRAL HEPATITIS IN THE CONTEXT OF PRIMARY HEALTH CARE	12
CLINICAL RESULTS IN PATIENTS WITH GASTROESOPHAGEAL VARICEAL BLEEDING IN THE ICU: ANALYSIS OF 85 CASES IN A TERTIARY CARE CENTRE	12

INCIDENCE AND PREDICTORS OF POST-TRANSPLANT MALIGNANCY IN LIVER TRANSPLANT RECIPIENTS: A SINGLE-CENTRE COHORT STUDY	12
Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT	12
P- 26 EFFECT OF PROTEIN X OF THE HEPATITIS B VIRUS AND HEXACHLOROBENZENE ON LIVER CELL GROWTH DYSREGULATION	12
PROGNOSTIC VALUE OF AST/ALT AND GGT/ALP RATIOS IN PATIENTS WITH CHOLANGIOCARCINOMA	12
LIPOUNITS: A NOVEL UNIT OF MEASUREMENT TO COMMUNICATE THE IMPACT OF DAILY HABITS ON LIVER FAT IN PATIENTS WITH MASLD	12
P-4 RISK OF HCC IN SOUTH AMERICANS ASSOCIATED WITH TLL1 VARIANT SINGLE NUCLEOTIDE POLYMORPHISM	11
Comment on “Pancreatic involvement and its prognostic impact in acute-on-chronic liver failure”	11
P- 18 ANASTROZOLE MAY NOT BE ASSOCIATED FATTY LIVER DISEASE AND HEPATIC FIBROSIS IN WOMEN WITH BREAST CANCER	11
Gradual dosing of ursodeoxycholic acid in mothers with intrahepatic cholestasis of pregnancy may improve composite neonatal outcome	11
Learning is not enough: enhancing the reach and rigor of hepatitis eLearning	11
Evaluation of the MELNa AGIB Scale to Predict Mortality in Patients with Cirrhosis and Variceal Hemorrhage.	10
Analysis of the impact of fatty acid metabolism on immunotherapy for hepatocellular carcinoma	10
Efficacy and safety of intravenous L-ornithine L-aspartate in patients with grade III and IV hepatic encephalopathy	10
Clues to decipher the origin of severe acute hepatitis in children: a new enigma during the COVID-19 pandemic	10
P- 107 EPIDEMIOLOGY, CLINICAL AND TISSUE CHARACTERISTICS OF A LARGE COHORT OF NAFLD/NASH FROM SOUTH AMERICA	10
FUELING THE FIRE: INFECTIONS TRIGGER AND MALNUTRITION DRIVES SEVERE ACLF IN CIRRHOSIS	9
Serum Immunoglobulin M levels and neutrophil/lymphocyte index as predictors of treatment response in patients with primary biliary cholangitis	9
Stroop test, Quickstroop, and the 1-min animal naming test for minimal hepatic encephalopathy diagnosis: A multicenter study in Mexico	9
P-41 MICRORNAs FROM EVs AS POTENTIAL LIVER FIBROSIS NON-INVASIVE BIOMARKERS IN CHRONIC HEPATITIS C	9
Identification of resistance mutations to DAA's against Hepatitis C Virus in infected subjects in Mexico	9
PROGNOSTIC ABILITY OF DIFFERENT SCORING SYSTEMS TO PREDICT VERY EARLY MORTALITY IN PATIENTS WITH CIRRHOSIS AND ACUTE-ON-CHRONIC LIVER FAILURE (ACLF)	9
Hepatic histologic findings in a murine model of diet induced-steatotic liver disease and acute alcohol intake	9
Characteristics of bacterial infections and prevalence of multidrug-resistant bacteria in hospitalized patients with liver cirrhosis in Germany	9
Jejunal lymphoma of large cell high grade B monomorphic in a patient with hepatic transplant	9
Evaluation of the early response to empirical treatment and its association with cultures in patients with spontaneous bacterial peritonitis (SBP)	9
NON-INVASIVE ASSESSMENT OF STEATOHEPATITIS AND LIVER FIBROSIS IN THE POPULATION AT RISK FOR METABOLIC STEATOTIC LIVER DISEASE	9
Prolonged-release pirfenidone in patients with compensated cirrhosis. Final results of the multicenter study ODISEA, controlled against placebo, plus standardized care_2023	9
MRI Imaging and Machine Learning Based Radiomics for Detection of Mixed HCC and CCA Tumors	9
Role of tamsulosin in recovery from thioacetamide-induced subchronic liver damage in a Wistar rat model	9
IL-18 discriminates highly frequent hepatitis E virus positive from negative blood donors in Mexico	8
MAFLD vs. MASLD: Consensus is unlike evidence!	8
OP-1 FEATURES OF IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI) IN LATIN AMERICA: LONG-TERM EXPERIENCE OF THE LATINDILI NETWORK	8
Differential effect of the allele G ADRB2 (rs1042714) and allele C ADRB3 (rs4994) and its association with metabolic-associated steatotic liver disease (MASLD) risk factors in Mexican population.	8
Autoimmune hemolytic anemia as a paraneoplastic syndrome in hepatocarcinoma, case report	8
Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH	8
Prevalence of liver cirrhosis based on the metabolic health and weight criteria: Report from the Korea National Health and Nutrition Examination Survey (KNHANES) data analysis	8
P-44 LONG-TERM SURVIVAL IN PATIENTS WITH LIVER TRANSPLANTATION	8
Editorial board	8
EDITORIAL BOARD	8
O-11 THE PUBLIC HEALTH POLICIES REDUCE THE LONG-TERM BURDEN OF ALCOHOL-ASSOCIATED LIVER DISEASE WORLDWIDE: DEVELOPMENT OF A PREPAREDNESS INDEX	8
P-14 SPONTANEOUS BACTERIAL PERITONITIS IN CIRRHOTIC PATIENTS: PREVALENCE AND ANTIBIOTIC RESISTANCE PATTERNS	8
A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease	8
O-13 SUB-OPTIMAL GLOBAL PUBLIC HEALTH POLICIES AND STRATEGIES TO TACKLE HEPATOCELLULAR CARCINOMA	8
Involvement of the hedgehog signaling pathway in liver diseases	8
EDITORIAL BOARD	8
P-87 TRANSCULTURAL ADAPTATION OF THE MEDITERRANEAN DIET TO THE DIETARY HABITS OF EACH GEOGRAPHICAL REGION OF ARGENTINA FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MA	8
Regulation of TGF-β1, 2, and 3 and IL-10 at systemic level in chronic liver disease	8
WHAT IS THE PROGNOSTIC VALUE OF A BLOOD TEST COUNT IN PATIENTS WITH ALCOHOLIC HEPATITIS?	7
Liver cirrhosis is a risk factor for poor prognosis of acute cholangitis caused by choledocholithiasis	7
Comment on “Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study”	7
TCD assessment in fulminant hepatic failure: Improvements in cerebral autoregulation after liver transplantation	7
Helicobacter pylori cagA/vacAs1-m1 strain is associated with high risk of fibrosis in metabolic-dysfunction-associated steatotic liver disease	7
NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS IN THE POPULATION WITH TYPE 2 DIABETES AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE	7
Comparison of surgical resection and transcatheter arterial chemoembolization for large hepatocellular carcinoma: a systematic review and meta-analysis	7
Aspartate aminotransferase‑to‑platelet ratio index (APRI) reliably excludes advanced fibrosis and cirrhosis in treated autoimmune hepatitis	7
Comment on “Liver stiffness measurement trajectory analysis for prognosis in patients with chronic hepatitis B and compensated advanced chronic liver disease”	7
Piloting eLearning initiatives: Computer-based training and telementoring for viral hepatitis care in public primary care setting	7
Endohepatology: current status and perspectives	7
Outcomes and risk of relapse after living donor and deceased donor liver transplantation for alcohol-associated liver disease	7
Prevalence of non-alcoholic fatty liver disease and liver fibrosis in a general population cohort from Argentina	7
CLINICAL CHARACTERIZATION OF HCC IN A SILENT REGION: REAL-WORLD DATA FROM A PROSPECTIVE COHORT IN CENTRAL AMERICA	7
Validation of the Hepamet fibrosis score in a multi-ethnic Asian population	7
EDITORIAL BOARD	7
LONG-TERM ALBUMIN THERAPY MAY IMPROVE SURVIVAL IN CIRRHOSIS WITH ASCITES: A SYSTEMATIC REVIEW AND META-ANALYSIS	7
Different measures of sodium intake and the risk of metabolic dysfunction-associated steatotic liver disease: Evidence from the UK Biobank	7
Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination	6
Demographic and clinical characteristics of MASLD and Met-ALD patients: Insights from NHANES 2017–2020	6
P-121 SEPTIC SHOCK IN LIVER CIRRHOSIS: A COHORT STUDY OF A UNIVERSITY HOSPITAL IN CHILE	6
Predictive role of microvesicles in cirrhotic patients: A promised land or a land of confusion? A narrative review	6
From NAFLD to MASLD: Promise and pitfalls of a new definition	6
Efficacy of prophylactic antibiotics in the adjuvant treatment of alcohol-related liver disease (ALD): A systematic review and meta-analysisProphylactic antibiotics in ALD	6
IMPORTANCE OF P450 POLYMORPHISM IN THE DEVELOPMENT OF DILI/HILI: HISTOLOGICAL AND BIOCHEMICAL FINDINGS	6
Risk factors for sarcopenia in cirrhotic patients under evaluation for liver transplantation.	6
Radiofrequency ablation and percutaneous ethanol injection versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis	6
Prevalence of hepatic encephalopathy in non-cirrhotic portal hypertension: A systematic review and meta-analysis	6
OP-5 ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) CRITERIA IN ALCOHOL-ASSOCIATED HEPATITIS: IMPLICATIONS FOR LIVER TRANSPLANTATION	6
Most Common Complications in Patients Post Liver Transplantation at a Hospital in Mexico.	6
Editorial board	6
ELIMINATION OF HEPATITIS C AMONG HEMODIALYSIS PATIENTS IN ALAGOAS, BRAZIL	6
Interpretive bias on research evidence: Striving to meet the trustworthiness criteria	6

Outcomes of liver transplantation in patients 70 years or older: a systematic review and meta-analysis	6
Efficacy of blood plasma spectroscopy for early liver cancer diagnostics in obese patients	6
Metabolic dysfunction: The silenced connection with fatty liver disease	6
P-75 INFLUENCE OF THE ARTERIAL HEPATIC FLOW IN ELASTOGRAPHY (2D SHEARWAVE) LIVER VALUES	6
O-14 NON-ALCOHOLIC FATTY LIVER DISEASE IS INFLUENCED BY THE INTERACTION OF HELICOBACTER PYLORI INFECTION AND G-ALLELE OF PNPLA3	6
P- 42 METABOLIC ASSOCIATED FATTY LIVER DISEASE AND BODY COMPOSITION MEASUREMENT	6
Clinical spectrum and long-term outcomes of non-cirrhotic portal venous system thrombosis in Hispanic population	6
ARTIFICIAL INTELLIGENCE IN PREDICTING THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH METABOLICALLY ASSOCIATED STEATOTIC LIVER DISEASE: DEVELOPMENT AND VALIDATION OF A PREDICTIVE MODEL IN 306 PA	6
Daytime napping and risk of liver cancer: A large population-based prospective cohort study	6
Good post-transplant outcomes using liver donors after circulatory death when applying strict selection criteria: a propensity-score matched-cohort study	5
P- 54 HEPATITIS C MICROELIMINATION IN FORMER DRUG USERS	5
P-77 TRIPLE THERAPY FOR DIFFICULT-TO-TREAT PRIMARY BILIARY CHOLANGITIS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS	5
Diethylnitrosamine and 2-acetylaminofluorene chronic administration leads to biochemical and histologic changes related to hepatocellular carcinoma in Wistar rats	5
Circular RNA hsa_circ_0098181 inhibits metastasis in hepatocellular carcinoma by activating the Hippo signaling pathway via interaction with eEF2	5
P- 39 N-ACETYL CYSTEINE ATTENUATES ALTERATIONS GENERATED IN EXPERIMENTAL LIVER STEATOSIS INDUCED BY CHRONIC ALCOHOL CONSUMPTION PLUS A HYPERCALORIC DIET	5
Colorimetric test for early diagnosis of spontaneous bacterial peritonitis.	5
Prevalence and evaluation of sleep disturbances in Mexican patients with hepatic cirrhosis through the application of the Pittsburgh sleep questionnaire	5
Hepatocellular carcinoma and upper gastrointestinal bleeding	5
Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease	5
Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.)	5
Evaluation of the ALBI, MELD, MELD-Na, MELD 3.0 score in patients with hepatocellular carcinoma treated with Yttrium-90 (90y)	5
Hepatitis C virus NS5A and core proteins regulate epithelial-mesenchymal transition biomarkers in hepatoma cells	5
Portal cholangiopathy secondary to cavernomatous transformation of the portal vein. Case report	5
Sarcopenia in patients with liver cirrhosis according to hepatic functional reserve	5
SARS-CoV-2 vaccination in liver transplant recipients: We still haven't found what we are looking for	5
Evaluation of the hepatoprotective effect of Flourensia cernua against the damage induced ischemia-reperfusion in Wistar rats.	5
P-7 EPIDEMIOLOGY OF AUTOIMMUNE HEPATITIS IN LATIN AMERICA: PRELIMINARY RESULTS FROM ALLATIN COHORT	5
Short-term response of p300 evoked potential in patients with minimal hepatic encephalopathy treated with l-ornithine, l-aspartate	5
O-11 ENHANCEMENT OF F4/80+CD11B-CD206+ KUPFFER CELLS IN LIVER TISSUE: EFFECT OF MARESIN-1 AS HEPATOPROTECTIVE AGENT	5
Clinical characteristics of liver injury in SARS-CoV-2 Omicron variant- and Omicron subvariant-infected patients	5
P-55 FIRST EVALUATION ALBI SCORE COULD BE A TOOL FOR RISK STRATIFICATION OF HCC DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS	5
OP-13 CHOLANGIOCARCINOMA IN LATIN AMERICA: A MULTICENTER OBSERVATIONAL STUDY ALERTS ON ETHNICAL DISPARITIES IN TUMOR PRESENTATION AND OUTCOME	5
Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis	4
LIVER FIBROSIS IN INDIVIDUALS WITH METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN LATIN AMERICA: INTERIM RESULTS FROM THE STELLA STUDY	4
Drug pricing for hepatitis B and C in Australia and Japan	4
Cavin1 activates the Wnt/β-catenin pathway to influence the proliferation and migration of hepatocellular carcinoma	4
Alcoholic cirrhosis-associated immune dysfunction: What does it imply for us?	4
O-37 AMOXICILLIN-CLAVULANATE INDUCED LIVER INJURY: TEN YEARS EXPERIENCE FROM LATINDILI REGISTRY.	4
Sarcopenia as a predictor of risk of minimal hepatic encephalopathy in patients with liver cirrhosis	4
CLIF-C-ACLF scale to predict mortality in pediatric patients with acute-on-chronic liver failure	4
P- 24 RISK OF MULTIPLE DRUG INTERACTIONS POTENTIALLY LINKED TO SAFETY IN PATIENTS RECEIVING PANGENOTYPIC DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C	4
HIGH PREVALENCE OF DILI/HILI IN A CENTER PARTICIPATING IN A MULTICENTER STUDY FOR DIAGNOSING ACUTE HEPATITIS IN BRAZIL	4
Limitations of MELD and MELD 3.0 for prognostication in patients with cirrhosis hospitalized with acute decompensation: an analysis of the ATTIRE trial	4
Influence of socioeconomic factors on liver transplant survival outcomes in patients with autoimmune liver disease in the United States	4
PRIMARY BILIARY CHOLANGITIS AT A TERTIARY CARE HOSPITAL	4
O-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL COHORT STUDY	4
P-121 CORRELATION BETWEEN HEPATOPULMONARY SYNDROME AND OXYGEN SATURATION PULSE OXIMETRY IN CIRRHOTIC PATIENTS	4
P- 73 ULTRASOUND VISUALIZATION OF THE LIVER	4
FROM POLICY TO PRACTICE: HEPATITIS C CARE INDICATORS IN URUGUAY BEFORE AND AFTER THE INTRODUCTION OF PUBLIC HEALTH STRATEGIES	4
MCM3 promotes hepatocellular carcinoma progression via Epithelial-mesenchymal Transition through AKT/Twist signaling pathway	4
A multinational survey of physician knowledge about management of chronic hepatitis C	4
NAFLD VS MAFLD. The evidence-based debate has come. Time to change?	4
Evaluation of the hypolipidemic effect of cinnamon essential oil in a model of acute damage induced by triton WR-1339	4
O-2 CHARACTERIZATION OF SERUM LEVELS OF BILE ACIDS, EXTRACELLULAR VESICLES AND ITS CARGO IN ALCOHOL-ASSOCIATED LIVER DISEASE	4
Hepatoprotective effects of N-acetylcysteine prevents hepatocellular carcinoma development induced experimentally.	4
Ethanol with thioacetamide murine model of alcoholic liver disease identifies hepatic pathways as targets for the human disease	3
Clinically significant portal hypertension in patients with primary biliary cholangitis: Clinicopathological features and prognostic value	3
P-3 FACTORS ASSOCIATED WITH AN IMPROVEMENT IN SEQUENTIAL LIVER STIFFNESS MEASURES BY TRANSIENT ELASTOGRAPHY IN MASLD PATIENTS WITH PREDIABETES AND TYPE 2 DIABETES.	3
P-109 ALKALINE PHOSPHATASE AND CIRRHOSIS AT DIAGNOSIS ARE ASSOCIATED WITH DEEP RESPONSE TO URSODEOXYCHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS	3
O-22 DIFFERENTIAL MUTATION PATTERN ASSOCIATED WITH HEPATITIS B E ANTIGEN SEROCONVERSION BETWEEN SUBGENOTYPE F1b CLUSTERS: POTENTIAL ROLE IN PATHOGENESIS	3
MORTALITY TRENDS AND RISK FACTORS IN ALCOHOL-ASSOCIATED HEPATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS	3
Integrated analyses and a novel nomogram for the prediction of significant fibrosis in patients	3
Impact of bilirubin molecular species on mortality in patients with acute on chronic liver failure (ACLF).	3
P-27 DESCRIPTIVE STUDY ON PATIENTS WITH HEPATOCARCINOMA IN A PUBLIC HOSPITAL 2018-2023	3
P- 48 EFFECT OF THE COMBINATION OF ORLISTAT AND L-CARNITINE ON THE QUALITY OF LIFE (SF.36) IN 16 OVERWEIGTH PATIENTS	3
Development and external validation of a machine-learning based model to predict pre-sarcopenia in MASLD population: Results from NHANES 2017–2018	3
Body mass index and diabetes predict severity of liver fibrosis across the spectrum of steatotic liver disease	3
P-85 IMPACT OF TECHNICAL NOTE No 32/2021 ON THE RATE OF LIVER TRANSPLANTS FOR REFRACTORY ASCITIS IN A TERTIARY HOSPITAL	3
P-50 CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS WITH ACUTE HEPATITIS B VIRUS IN A PUBLICAL HOSPITAL IN CHILE FROM 2015 TO 2022.	3
P- 44 HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS IN A PARAGUAYAN LIVER REFERENCE CENTER: CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS	3
“Hepatocellular carcinoma surveillance: Current challenges in Latin America”	3
P- 39 CLINICAL SIGNIFICANCE OF GRADE 1 HEPATIC ENCEPHALOPATHY IN PATIENTS HOSPITALIZED FOR COMPLICATIONS OF CIRRHOSIS	3
A novel nomogram for predicting HBeAg seroclearance in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues	3
CHOLANGIOCARCINOMA IN INDIVIDUALS WITH CHRONIC LIVER DISEASE IS DIAGNOSED EARLIER, LEADING TO BETTER PROGNOSIS	3
O-20 EFFECTS OF ISOCALORIC AND NEGATIVE CALORIE BALANCE EXERCISE ON SERUM LEVELS OF INSULIN-LIKE GROWTH FACTOR TYPE 1 IN SUBJECTS WITH INITIAL AND ADVANCED FATTY LIVER	3
P-12 METHYL GROUP DONOR SUPPLEMENTATION IN A MetALD MODEL: REGULATION OF GUT MICROBIOTA AND METABOLIC PARAMETERS	3
P- 56 TUBERCULOSIS IN LIVER TRANSPLANT RECIPIENTS: EXPERIENCE OF A SINGLE CENTER	3
Examining the prevalence of hepatic steatosis and advanced fibrosis using non-invasive measures across Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019	3
O-3 DEVELOPMENT OF LENTIVIRAL VECTORS FOR INHIBITION OF HEPATITIS B VIRUS VIA SMALL INTERFERING RNA	3
Liver fibrosis: More than meets the eye	3
O-1 ECONOMIC IMPACT OF LONG-TERM ALBUMIN INFUSIONS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS AND UNCOMPLICATED ASCITES FROM THE BRAZILIAN PUBLIC AND PRIVATE HEALTHCARE SYSTEMS PERSPECTIVES	3
Response to: MAFLD treatment: emphasizing the concept of “homology of medicine and food”	3
ANALYSIS OF NEUTROPHIL-TO-LYMPHOCYTE RATIO AND C-REACTIVE PROTEIN IN CIRRHOTIC PATIENTS WITH BACTERIAL, FUNGAL, AND VIRAL INFECTIONS: A CROSS-SECTIONAL STUDY	3
Correlation of Cardiovascular Risk Score with Alterations in Carotid Intima-Media Thickness in Patients with MASLD	3
O- 5 HCC RISK SCORE PRE AND POST SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS TREATED FOR CHRONIC HEPATITIS C	3
O-17 NUTRICIONAL AND PHYSICAL THERAPHY IMPROVES LIVER FRAILTY INDEX IN LISTED PATIENTS WITH CIRRHOSIS: RANDOMIZED CONTROLLED TRIAL. INTERIM ANALYSIS	3
Early living donor liver transplantation for alcohol-associated hepatitis	2
Letter to the editor—Opinion on article by Rodriguez-Alvarez F et al.	2
EXPERIENCE IN THE TREATMENT OF HEPATITIS C IN PREGNANT PATIENTS AT THE HEPATITIS CLINIC OF THE VERACRUZ HIGH SPECIALTY HOSPITAL	2
The GDF11 represses the Stat3 signaling pathway, conferring metabolic, inflammatory, and oncogenic restrictions in cells derived from human hepatocellular carcinoma.	2
The role of the prognostic nutritional index as a prognostic factor in patients with hepatocellular carcinoma.	2
MAFLD treatment: Emphasizing the concept of “homology in medicine and food”	2
Simplification of the diagnostic approach and treatment of Hepatitis C Virus.	2
STEATOTIC HEPATOCYTES SHOWN REDUCED CYP450 EXPRESSION AND IN VITRO RESISTANCE TO DRUG-INDUCED TOXICITYSTEATOTIC HEPATOCYTES SHOWN REDUCED CYP450 EXPRESSION AND IN VITRO RESISTANCE TO DRUG-INDUCED TOXI	2
Psoriasis and steatotic liver disease: Are PNPLA3 and TM6SF2 polymorphisms suitable for the hepato-dermal axis hypothesis?	2